Redhill BiopharmaSTU:2RH 18 EBITDA Margin % is 126.03% as of Dec. 2025. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Redhill Biopharma ranks worse than 98.32% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Redhill Biopharma's EBITDA for the
six
months ended in Dec. 2025 was €-4.08 Mil. Redhill Biopharma's Revenue for the
six
months ended in Dec. 2025 was €-3.24 Mil. Therefore, Redhill Biopharma's EBITDA margin for the quarter that ended in Dec. 2025 was 126.03%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Redhill Biopharma EBITDA Margin % Related Terms
Redhill Biopharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Redhill Biopharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2RH vs LVRLF, BUDZ, GELS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redhill Biopharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Redhill Biopharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Redhill Biopharma (STU:2RH) has a EBITDA Margin % of 126.03% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Redhill Biopharma and its competitors. According to the industry distribution chart, Redhill Biopharma ranks #939 out of 955 companies in the Drug Manufacturers industry, placing it in the top 98.3%.
Is Redhill Biopharma's EBITDA Margin % too high?
Redhill Biopharma's current EBITDA Margin % is 126.03%. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Redhill Biopharma's value of 126.03% is 917.2% above this industry median. Based on the distribution chart, Redhill Biopharma ranks #939 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's EBITDA Margin % compare to LVRLF and BUDZ?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #939 out of 955 companies for EBITDA Margin %. This places Redhill Biopharma in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Redhill Biopharma's value of 126.03% is 917.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Redhill Biopharma's current EBITDA Margin % of 126.03% is 917.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Redhill Biopharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redhill Biopharma's current EBITDA Margin % is 126.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current EBITDA Margin % of 126.03%. The current EBITDA Margin % is 126.03% and 917.2% above the Drug Manufacturers industry median of 12.39. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current EBITDA Margin % is 126.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score
Get the complete analysis for STU:2RH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RH has been successfully added to your 
